Global Information
회사소개 | 문의 | 비교리스트

만성 폐쇄성 폐질환(COPD) : 파이프라인 리뷰

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 04월 상품 코드 264708
페이지 정보 영문 552 Pages
가격
US $ 2,000 ₩ 2,396,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,792,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,189,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


만성 폐쇄성 폐질환(COPD) : 파이프라인 리뷰 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2020
발행일 : 2020년 04월 페이지 정보 : 영문 552 Pages

만성 폐쇄성 폐질환(COPD)은 폐에서의 호흡과 흡기가 불완전해져서 호흡 곤란을 일으키는 폐질환입니다. 폐의 공기 유출입이 방해를 받고, 기침, 피로, 흉통 등의 증상이 시간이 지나면서 악화되어 합병증도 증가합니다. 가장 큰 위험요인은 흡연이지만, 화학물질 및 대기오염 등도 COPD가 진행되는 요인입니다. 금연과 기타 약물 투여에 의해 진행이 억제될 수 있습니다.

만성 폐쇄성 폐질환(COPD : Chronic Obstructive Pulmonary Disease) 치료제 개발 상황에 대해 조사 분석했으며, 파이프라인 제품 개요, 임상시험 단계별 제품 개요, 주요 기업 개요, 치료제 개요, 파이프라인 제품 최신 동향, 최신 뉴스와 프레스 릴리스 등의 정보를 전해드립니다.

목차

서론

만성 폐쇄성 폐질환(COPD) 개요

치료제 개발

치료제 평가

치료제 개발 참여 기업

약제 프로파일

개발 휴지 상태인 제품

개발이 중지되고 있는 제품

제품 개발 마일스톤

부록

도표

LSH 17.06.05

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..5), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..6), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..4), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..5), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..6), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..7), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..8), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..9), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..3), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..3), H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by 3SBio Inc, H1 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AB Science SA, H1 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AB2 Bio Ltd, H1 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Adamis Pharmaceuticals Corp, H1 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Afimmune Biopharma Ltd, H1 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Aibios Co Ltd, H1 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AlgiPharma AS, H1 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Allinaire Therapeutics LLC, H1 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Amgen Inc, H1 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Angiocrine Bioscience Inc, H1 2020

List of Figures

  • Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Obstructive Pulmonary Disease - Pipeline Review, H1 2020, provides an overview of the Chronic Obstructive Pulmonary Disease (Respiratory) pipeline landscape.

Chronic obstructive pulmonary disease (COPD) is a group of lung diseases. It is characterized by inability to completely breathe out air from the lungs leading to shortness of breath. The airflow to the lungs is further blocked. Other symptoms include cough, fatigue and chest pain. The disease tends to worsen over the time hence increasing the complications. The risk factors involved in causing COPD include smoking as the primary reason. Exposure to chemicals and air pollution also contribute in the development of COPD.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Obstructive Pulmonary Disease - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Chronic Obstructive Pulmonary Disease (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Obstructive Pulmonary Disease (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 8, 38, 15, 3, 77, 21 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 8 and 2 molecules, respectively.

Chronic Obstructive Pulmonary Disease (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Obstructive Pulmonary Disease (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Chronic Obstructive Pulmonary Disease (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chronic Obstructive Pulmonary Disease (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chronic Obstructive Pulmonary Disease (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Obstructive Pulmonary Disease (Respiratory)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chronic Obstructive Pulmonary Disease (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Chronic Obstructive Pulmonary Disease (COPD) - Overview
  • Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics Development
  • Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics Assessment
  • Chronic Obstructive Pulmonary Disease (COPD) - Companies Involved in Therapeutics Development
  • Chronic Obstructive Pulmonary Disease (COPD) - Drug Profiles
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects
  • Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products
  • Chronic Obstructive Pulmonary Disease (COPD) - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q